Delayed effects of acute whole body lethal radiation exposure in mice pre-treated with BBT-059

Author:

Sharma Neel K.,Holmes-Hampton Gregory P.ORCID,Kumar Vidya P.,Biswas Shukla,Wuddie Kefale,Stone Sasha,Aschenake Zemenu,Wilkins William L.,Fam Christine M.,Cox George N.,Ghosh Sanchita P.

Abstract

AbstractThe threat of nuclear exposure is heightened and it is imperative to identify potential countermeasures for acute radiation syndrome. Currently no countermeasures have been approved for prophylactic administration. Effective countermeasures should function to increase survival in the short term as well as to increase the overall prognosis of an exposed individual long term. Here we describe the use of a promising radiation countermeasure, BBT-059, and the results of a long term mouse study (up to 12 months) in the male CD2F1 strain using 60Co gamma irradiation (~0.6 Gy/min, 7.5–12.5 Gy). We report the dose reduction factor of 1.28 for BBT-059 (0.3 mg/kg) compared to control administered 24 h prior to irradiation. In the long term study animals showed accelerated recovery in peripheral blood cell counts, bone marrow colony forming units, sternal cellularity and megakaryocyte numbers in drug treated mice compared to formulation buffer. In addition, increased senescence was observed in the kidneys of animals administered control or drug and exposed to the highest doses of radiation. Decreased levels of E-cadherin, LaminB1 and increased levels of Cyc-D and p21 in spleen lysates were observed in animals administered control. Taken together the results indicate a high level of protection following BBT-059 administration in mice exposed to lethal and supralethal doses of total body gamma-radiation.

Funder

United States Department of Defense | Uniformed Services University | Armed Forces Radiobiology Research Institute, Uniformed Services University

AFRRI Intramural funding RAB23338

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Reference59 articles.

1. Administration, U.S. FDA, http://1.usa.gov/22Aj474 (Silver Spring, MD, 2015).

2. Administration, U.S. FDA, http://1.usa.gov/1Tpsbov (Silver Spring, MD: U.S, 2015).

3. Administration, U.S. FDA. FDA approves Leukine for Acute Radiation Syndrome. (2018).

4. Health, U. D. o., Services, H., Food & Administration, D. (2017).

5. Paul, S. R. et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proceedings of the National Academy of Sciences of the United States of America 87, 7512–7516, https://doi.org/10.1073/pnas.87.19.7512 (1990).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3